Personal neoantigen cancer vaccines: The momentum builds

Neoantigen-based cancer vaccines designed to target the unique immunogenic mutations arising in each patient’s tumor are breathing new life into a struggling approach. Data continue to demonstrate the importance of neoantigens in immune control of cancer. Despite manufacturing complexity, outstandin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fritsch, Edward F, Hacohen, Nir, Wu, Catherine J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121338/
https://www.ncbi.nlm.nih.gov/pubmed/25101225
http://dx.doi.org/10.4161/onci.29311
_version_ 1782329220269080576
author Fritsch, Edward F
Hacohen, Nir
Wu, Catherine J
author_facet Fritsch, Edward F
Hacohen, Nir
Wu, Catherine J
author_sort Fritsch, Edward F
collection PubMed
description Neoantigen-based cancer vaccines designed to target the unique immunogenic mutations arising in each patient’s tumor are breathing new life into a struggling approach. Data continue to demonstrate the importance of neoantigens in immune control of cancer. Despite manufacturing complexity, outstanding questions and desired further improvements, neoantigen vaccines are currently undergoing clinical evaluation.
format Online
Article
Text
id pubmed-4121338
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-41213382014-08-06 Personal neoantigen cancer vaccines: The momentum builds Fritsch, Edward F Hacohen, Nir Wu, Catherine J Oncoimmunology Author's View Neoantigen-based cancer vaccines designed to target the unique immunogenic mutations arising in each patient’s tumor are breathing new life into a struggling approach. Data continue to demonstrate the importance of neoantigens in immune control of cancer. Despite manufacturing complexity, outstanding questions and desired further improvements, neoantigen vaccines are currently undergoing clinical evaluation. Landes Bioscience 2014-06-25 /pmc/articles/PMC4121338/ /pubmed/25101225 http://dx.doi.org/10.4161/onci.29311 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Fritsch, Edward F
Hacohen, Nir
Wu, Catherine J
Personal neoantigen cancer vaccines: The momentum builds
title Personal neoantigen cancer vaccines: The momentum builds
title_full Personal neoantigen cancer vaccines: The momentum builds
title_fullStr Personal neoantigen cancer vaccines: The momentum builds
title_full_unstemmed Personal neoantigen cancer vaccines: The momentum builds
title_short Personal neoantigen cancer vaccines: The momentum builds
title_sort personal neoantigen cancer vaccines: the momentum builds
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121338/
https://www.ncbi.nlm.nih.gov/pubmed/25101225
http://dx.doi.org/10.4161/onci.29311
work_keys_str_mv AT fritschedwardf personalneoantigencancervaccinesthemomentumbuilds
AT hacohennir personalneoantigencancervaccinesthemomentumbuilds
AT wucatherinej personalneoantigencancervaccinesthemomentumbuilds

Ejemplares similares